|Slideshows|November 6, 2017

Harbingers of Dementia-or Not?

Hypertension, loss of sense of smell, personality changes: which can predict dementia?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

The State of Alzheimer Disease Care: An Update From Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

ByLeah Kuntz,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

August 3rd 2026

This Month In Alzheimer Disease: July’s Pharmacology and Research Developments

ByJessica Walters

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

ByJessica Walters,Aaron Ritter, MD

July 30th 2026

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

ByJessica Walters,Kirsty J. Dixon, PhD

July 29th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Harbingers of Dementia-or Not?

Related Content

The State of Alzheimer Disease Care: An Update From Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

This Month In Alzheimer Disease: July’s Pharmacology and Research Developments

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FAQ: What Clinicians Need to Know About Postpartum Psychosis

Psychiatry Mid-Year Market Update 2026: Persistent Demand, Widening Valuation Gap, and Workforce/Regulatory Realities

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

New in Narcolepsy: Pharmacology Updates

Morning Rounds: News From August 3-9